A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study).
Phase of Trial: Phase II/III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 22 Jun 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 22 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.